Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic ...

Aeglea BioTherapeutics is rebranding, unveiling a new name and a host of leadership changes. The company announced Monday that it will go by its new name, Spyre Therapeutics, and has a host of ...

Julian Harrison, an analyst from BTIG, maintained the Buy rating on Spyre Therapeutics (SYRE – Research Report). The associated price target was raised to $40.00. Julian Harrison has given his ...

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in ...

Julian Harrison has given his Buy rating due to a combination of factors surrounding the promising developments at Spyre Therapeutics. The market for anti-TL1A assets remains robust, and Spyre’s ...

Spyre Therapeutics has a 52 week low of $10.91 and a 52 week high of $40.84. The company has a market cap of $805.64 million, a PE ratio of -1.79 and a beta of 3.05.

Spyre Therapeutics (SYRE) announced Spyre has been added to the Nasdaq Biotechnology Index effective prior to market open, Monday, December 23. Pick the best stocks and maximize your portfolio ...

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic ...

Preclinical data for SPY001 demonstrate the potential for improved dosing over standard of care, including the potential for dosing every eight or twelve weeks compared to dosing every two weeks ...